Literature DB >> 7264887

Simultaneous determination of imipramine, desipramine, and their 2-hydroxy metabolites in plasma by ion-pair reversed-phase high-performance liquid chromatography with amperometric detection.

R F Suckow, T B Cooper.   

Abstract

An ion-pair reversed-phase high-performance liquid chromatographic (HPLC) method, using an electrochemical detector, is presented for the simultaneous and rapid quantitation of imipramine desipramine, and their 2-hydroxylated metabolites in plasma. The drugs are extracted from 1 ml of plasma at pH 9.7 with ether, back-extracted into 0. M HCl, and reextracted into ether following alkalinization. An efficient electrochemical oxidation reaction at the detector electrode affords a low detection level of approximately 5 ng/ml in a mobile phase of acetonitrile--acetate buffer (40:60) containing 0.005 M heptanesulfonate. Patient data are presented as correlations between the plasma level of each hydroxy metabolite and its respective parent compound. The method is applicable to the laboratory experienced in HPLC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7264887     DOI: 10.1002/jps.2600700307

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  10 in total

1.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  On mixtures of three normal populations caused by monogenic inheritance: application to desipramine metabolism.

Authors:  K J Miescke; M N Musa
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

3.  Quantification of imipramine and its major metabolites in whole blood, brain, and other tissues of the rat by liquid chromatography.

Authors:  S A Stout; C L DeVane
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  Cimetidine-induced alterations in desipramine plasma concentrations.

Authors:  J D Amsterdam; D J Brunswick; L Potter; M J Kaplan
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Effects of desipramine, trifluoperazine and other inhibitors of calmodulin on the secretion of catecholamines from the adrenal medulla and postganglionic sympathetic nerves of the salivary gland.

Authors:  A R Wakade; T D Wakade
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

6.  Effects of desipramine on irritable bowel syndrome compared with atropine and placebo.

Authors:  D S Greenbaum; J E Mayle; L E Vanegeren; J A Jerome; J W Mayor; R B Greenbaum; R W Matson; G E Stein; H A Dean; N A Halvorsen
Journal:  Dig Dis Sci       Date:  1987-03       Impact factor: 3.199

7.  Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites.

Authors:  A E Balant-Gorgia; L P Balant; C Genet; P Dayer; J M Aeschlimann; G Garrone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of drugs used to treat urge incontinence.

Authors:  David R P Guay
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

9.  Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis.

Authors:  Y Sato; S Shibanoki; M Sugahara; K Ishikawa
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

10.  Electrochemical Characterization of Central Action Tricyclic Drugs by Voltammetric Techniques and Density Functional Theory Calculations.

Authors:  Edson Silvio Batista Rodrigues; Isaac Yves Lopes de Macêdo; Larissa Lesley da Silva Lima; Douglas Vieira Thomaz; Carlos Eduardo Peixoto da Cunha; Mayk Teles de Oliveira; Nara Ballaminut; Morgana Fernandes Alecrim; Murilo Ferreira de Carvalho; Bruna Guimarães Isecke; Karla Carneiro de Siqueira Leite; Fabio Bahls Machado; Freddy Fernandes Guimarães; Ricardo Menegatti; Vernon Somerset; Eric de Souza Gil
Journal:  Pharmaceuticals (Basel)       Date:  2019-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.